MAY 30, 2014 03:00 PM PDT

Opportunities to simplify clinical lipid assessment

Speakers
  • Clinical Associate Professor, Dept of Biochemistry, Royal Prince Alfred Hospital
    Biography
      David Sullivan is a physician and chemical pathologist in the Department of Clinical Biochemistry at Royal Prince Alfred Hospital.  This includes conjoint appointment as Clinical Associate Professor, Central Clinical School, Faculty of Medicine and Charles Perkins Centre, University of Sydney. David has a long-term interest in lipid metabolism with particular emphasis on the gene environment interactions contributing to cardiovascular disease. He has been involved in the early use of many forms of lipid-lowering intervention. He remains a national leader of efforts to improve the detection and management of severe inherited dyslipidaemia, such as that seen in Familial Hypercholesterolaemia. David has experience in several international clinical posts, including World Health Organization (WHO) Fellowship at the MRC Lipoprotein Unit, Royal Postgraduate School of Medicine, Hammersmith Hospital, London and co-ordination of international clinical studies from the WHO reference lipid laboratory in Wageningen, Netherlands. In addition to his clinical activities in Australia, he has served on numerous clinical committees including the management committees of the LIPID and FIELD trials. Current research interests are focussed on biomarkers, post-prandial metabolism and novel therapies.

    Abstract:

    Laboratory assessment of serum lipid and lipoprotein levels is essential for the management of the risk of atherothrombotic cardiovascular disease (CVD). Traditionally, this has involved the measurement of fasting levels of total and HDL cholesterol, as well as calculation or direct measurement of LDL cholesterol (LDL-C). Contemporaneous fasting triglyceride levels are required for calculation of LDL-C.

    Several recent developments have created uncertainty concerning the current and future use of LDL-C as the main focus of CVD management. This presentation will examine the clinical and therapeutic insights that have prompted a reduction in the emphasis on LDL-C. It will also explore alternatives that may enhance laboratory CVD risk assessment, some of which are relatively simple.


    Show Resources
    You May Also Like
    MAY 22, 2018 08:00 AM PDT
    C.E. CREDITS
    MAY 22, 2018 08:00 AM PDT
    DATE: May 22, 2018TIME: 08:00AM PDT The nuclear receptors pregnane X receptor (PXR) and constitutive androstane receptor (CAR) are closely related transcription factors that...
    MAY 24, 2018 09:30 AM PDT
    C.E. CREDITS
    MAY 24, 2018 09:30 AM PDT
    DATE: May 24, 2018 TIME: 9:30PM PDT The current gold standard in in vitro pre-clinical cancer treatment screening remain cell lines,...
    MAY 03, 2018 11:00 AM PDT
    MAY 03, 2018 11:00 AM PDT
    DATE: May 3, 2018TIME: 11:00AM PDT, 2:00PM EDTWhile stress is one of the leading causes of neuropsychiatric disorders, the molecular underpinnings of how stress induces alterations in b...
    APR 27, 2018 10:00 AM PDT
    C.E. CREDITS
    APR 27, 2018 10:00 AM PDT
    DATE: April 27, 2018TIME: 10:00am PST, 1:00pm ESTGlioblastoma (GBM) and Medulloblastoma (MB) are the most common adult and paediatric brain tumours, both of which can have devastating c...
    JUN 20, 2018 10:00 AM EDT
    C.E. CREDITS
    JUN 20, 2018 10:00 AM EDT
    DATE: June 20, 2018TIME: 07:00AM PDT, 10:00AM EDTIntroducing GE’s New Lyo-StableTM service. Sepsis is one of the top challenges facing hospitals in terms of clinical outcomes...
    JUN 26, 2018 06:00 AM PDT
    C.E. CREDITS
    JUN 26, 2018 06:00 AM PDT
    Date: June 26, 2018Time: 6:00 a.m. PDT, 9:00 a.m. EDT, 1500 CEST Today’s hematology analyzers employ various methods for enumerating platelets. These methods include: e...
    Loading Comments...